West Pharmaceutical Services, Inc.
NYSE:WSTMedical - Instruments & Supplies
+$5.04 today
- Market cap
- $28.14B
- Beta
- 1.18
- P/E (TTM)
- 43.6
- EPS (TTM)
- $7.54
- Dividend yield
- 0.26%
Volume 0.59M
Average 0.85M
WST Net Income
Bottom-line profit, the starting point for calculating cash from operations.
West Pharmaceutical Services, Inc.NYSE: WST
Net Income · Q2 FY2026 · quarter ended Jun 2026
Net income grows in line with its trailing trend
Q2 FY2026 net income of $154M rose 16.8% year over year, ahead of the +15.8% change in trailing-twelve-month net income. Sequentially, it rose 11.0% from the prior quarter. Over 3 fiscal years it compounded at -5.5% a year.
Context
- Net income amounted to 16.1% of revenue in FY2025, down 1.0 pp from a year earlier.
- Net income increased in 2 of the last 3 fiscal years.
What to watch
Whether net income reaches the consensus estimate from 12 analysts of $676.7M (+37.1%) for the fiscal year ending Dec 2026, a step up from the +0.2% reported in FY2025.
Sources:Cash Flow Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterJun 2026
- $154M+11.0% QoQ
- Last fiscal yearDec 2025
- $493.7M+0.2% YoY
- LTMJun 2026
- $564.9M+15.8% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +16.8% | +11.3% | -5.5 pp |
| 1 year | +0.2% | +37.1% | +36.9 pp |
| 3-year CAGR | -5.5% | +18.8% | +24.4 pp |
| 5-year CAGR | +16.3% | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Net Income history
USD · from the cash flow
- Latest · FY2025
- 493.7M USD
- Year-over-year change
- +0.2%
- 4-year CAGR
- -7.1%
| Period | Period end | Net Income | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 493.7M | +0.2% |
| FY2024 | 2024-12-31 | 492.7M | -17.0% |
| FY2023 | 2023-12-31 | 593.4M | +1.3% |
| FY2022 | 2022-12-31 | 585.9M | -11.5% |
| FY2021 | 2021-12-31 | 661.8M | — |
Net Income vs competitors
How WST compares with its peers on the latest reported figures
- Peers report in different currencies, so net income is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +15.8% is the 2nd highest of 5, against a peer median of -12.3%.
- Net income amounts to 17.0% of revenue for WST, versus a peer median of 5.4%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $564.9M USD | +15.8% | -5.5% | 17.0% | |
| LTM Jun 2026 | $307.89M USD | -21.3% | +17.9% | 7.8% | |
| LTM Jun 2026 | €173.64M EUR | -3.3% | -10.5% | 14.2% | |
| LTM Jun 2026 | $30.09M USD | +181.4% | — | 1.4% | |
| LTM Mar 2026 | $2.96M USD | -87.7% | -68.0% | 3.0% | |
| Peer median (excluding WST) | — | -12.3% | -10.5% | 5.4% | |
Competitors are the stored peer set for WST. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | 661.8M | 585.9M | 593.4M | 492.7M | 493.7M |
| Depreciation & Amortization | 122.3M | 120.6M | 137.3M | 155.4M | 171.4M |
| Deferred Income Tax | (42.9M) | (30.8M) | 37.5M | 0 | (13.7M) |
| Stock-Based Compensation | 37.5M | 23.7M | 23.3M | 18.7M | 23.8M |
| Change in Working Capital | (193.8M) | (15M) | (20.4M) | 2.9M | 79.8M |
| Accounts Receivables | (123.5M) | (35.6M) | 4M | (58.8M) | 6.9M |
| Inventory | (86.5M) | (49.8M) | (13.5M) | 42M | (62.8M) |
| Accounts Payables | 16.8M | (2.8M) | 4.4M | 2.9M | 17.9M |
| Other Working Capital | (600K) | 73.2M | (15.3M) | 16.8M | 117.8M |
| Other Non-Cash Items | (900K) | 36.1M | 5.4M | (16.3M) | (200K) |
| Operating Cash Flow | 584M | 724M | 776.5M | 653.4M | 754.8M |
| Capital Expenditures | (253.4M) | (284.6M) | (362M) | (377M) | (285.9M) |
| Acquisitions (Net) | (2.2M) | 0 | 0 | 0 | 0 |
| Purchases of Investments | 0 | 0 | 0 | 0 | 0 |
| Sales of Investments | 0 | 0 | 0 | 0 | 0 |
| Other Investing Activities | 2.5M | (3.6M) | (6.7M) | (1.7M) | 0 |
| Investing Cash Flow | (253.1M) | (288.2M) | (368.7M) | (378.7M) | (285.9M) |
| Debt Repayment | (2.2M) | (44.3M) | (2.3M) | (27.6M) | (1.1M) |
| Common Stock Issued | 0 | 0 | 0 | 0 | 18.2M |
| Common Stock Repurchased | (151.9M) | (222.2M) | (451.2M) | (566.6M) | (134M) |
| Dividends Paid | (51.1M) | (54.1M) | (57M) | (59.1M) | (61.2M) |
| Other Financing Activities | 37.1M | 27M | 50.9M | 30.7M | (7M) |
| Financing Cash Flow | (168.1M) | (293.6M) | (459.6M) | (622.6M) | (185.1M) |
| Effect of Forex Changes | (15.7M) | (10.5M) | 11.4M | (21.4M) | 22.9M |
| Net Change in Cash | 147.1M | 131.7M | (40.4M) | (369.3M) | 306.7M |
| Free Cash Flow | 330.6M | 439.4M | 414.5M | 276.4M | 468.9M |
West Pharmaceutical Services, Inc.
NYSE:WST
Intrinsic Alpha fair value
Locked
Current Price
$404.02
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.